Shanghai Sylon Biotechnology

Shanghai Sailun Biological Medicine is a leading Chinese biotechnology company specializing in the research, development, and manufacturing of antitoxin and antiserum products. Established in 1999 and headquartered in Shanghai, the company is a dominant player in the domestic market for antivenoms and immunoglobulins used to treat life-threatening conditions such as snake bites, tetanus, and rabies. Its core product portfolio includes equine anti-tetanus immunoglobulin and various anti-snake venom serums. The company is publicly traded on the Shanghai Stock Exchange (SSE: 688163) and maintains a significant manufacturing presence in China to support public health and biosafety needs.